Previous 10 | Next 10 |
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia (TD), including utilization and patient satisfaction AUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year long-term data 1,2 ...
2023-06-02 09:30:53 ET Akebia Therapeutics ( NASDAQ: AKBA ) announced Friday that its subsidiary Keryx Biopharmaceuticals and licensing partner Panion & BF Biotech settled the last patent litigation related to generic versions of its kidney disease therapy Auryxia. Counterpa...
2023-05-25 01:43:01 ET Summary David Abrams’ 13F portfolio value increased this quarter from $2.80B to $3.16B. The number of positions remained steady at 15. Cantaloupe stake was increased while decreasing Teva Pharmaceutical. The top three positions are Lithia Motors, ...
UZEDY significantly reduced the risk of relapse by up to 80% and prolonged the time to impending relapse by up to 5.0 times while having a similar safety profile to other formulations of risperidone 1,2 The U.S. Food and Drug Administration (FDA) approved UZEDY on April 28, 2023 for t...
2023-05-19 03:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-18 09:07:15 ET Teva Pharmaceutical ( NYSE: TEVA ) added ~3% pre-market Thursday after announcing what its management identified as a new “pivot to growth” strategy while Evercore ISI upgraded its shares. The launch of the new strategic framework comes a...
Return to growth by accelerating a strong innovative medicines portfolio Expand innovative pipeline and focus on core therapeutic areas with first-in-class and best-in-class opportunities Sustain generics powerhouse based on high-value and complex products Focus the business on areas ...
2023-05-16 15:15:31 ET The Biden administration is summoning manufacturers of opioid reversal therapy naloxone in a bid to reduce prices and improve access, Reuters reported Tuesday, quoting a spokesperson for the White House Office of National Drug Control Policy. Dr. Rahul Gupta, ...
2023-05-16 08:52:10 ET British drugmaker AstraZeneca ( NASDAQ: AZN ) has decided to leave the Pharmaceutical Research and Manufacturers of America (PhRMA), the major pharmaceutical lobby group in the U.S., the company said. The influential industry trade group counts pharma gian...
2023-05-15 10:40:32 ET The U.S. Supreme Court on Monday denied to hear an appeal filed by Teva Pharmaceuticals ( NYSE: TEVA ), leaving in place $235M awarded to GSK ( NYSE: GSK ) in relation to a high-stakes patent dispute over a generic version of the British drugmaker's Co...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment Topline results for both UC and CD now anticipated in Q4 2024 Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug (anti-TL1A) for moderate-...
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...